Compare · CNTB vs NVO
CNTB vs NVO
Side-by-side comparison of Connect Biopharma Holdings Limited (CNTB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNTB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $168.79B, about 2948.7x CNTB ($57.2M).
- Over the past year, CNTB is down 50.6% and NVO is down 30.7% - NVO leads by 19.9 points.
- CNTB has been more active in the news (7 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 8 for CNTB).
- Company
- Connect Biopharma Holdings Limited
- Novo Nordisk A/S
- Price
- $0.89-1.85%
- $38.86-0.94%
- Market cap
- $57.2M
- $168.79B
- 1M return
- -30.77%
- -10.05%
- 1Y return
- -50.58%
- -30.70%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 7
- 4
- Recent ratings
- 8
- 25
Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CNTB
- Leerink Partners resumed coverage on Connect Biopharma with a new price target
- SEC Form SCHEDULE 13G filed by Connect Biopharma Holdings Limited
- Director Xanthopoulos Kleanthis Gabriel was granted 5,000 units of Ordinary Shares, increasing direct ownership by 6% to 91,554 units (SEC Form 4)
- Director Liu Jean I was granted 8,984 units of Ordinary Shares, increasing direct ownership by 76% to 20,763 units (SEC Form 4)
- 3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours
- Connect Biopharma Holdings Limited filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
- Connect Biopharma Holdings Limited filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
- Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank